IMMX
Immix Biopharma, Inc.
Price Chart
Latest Quote
$10.11
+0.08 (+0.80%)
Current Price
| Previous Close | $10.03 |
| Open | $9.95 |
| Day High | $10.25 |
| Day Low | $9.80 |
| Volume | 359,494 |
Stock Information
| Shares Outstanding | 71.19M |
| Total Debt | $1.04M |
| Cash Equivalents | $90.58M |
| Net Income | $-34.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $719.73M |
| EPS (TTM) | $-0.92 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $456.75M |
| Income | $-34.98M |
| Book/sh | $1.59 |
| Cash/sh | $1.27 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 8.59 |
| Current Ratio | 8.76 |
| Debt/Eq | 1.23 |
Returns & Margins
| ROA | -38.97% |
| ROE | -74.46% |
Ownership
| Insider Ownership | 17.56% |
| Institutional Ownership | 45.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.63 |
| P/B | 6.35 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $19.75 |
Technical Indicators
| SMA20 | $8.77 |
| SMA50 | $9.24 |
| SMA200 | $6.45 |
| RSI | 72.41 |
| ATR | 0.7346 |
| Shares Float | 43.40M |
| Short Float | 6.85% |
| Short Ratio | 3.15 |
| Volatility | 0.10 |
| Rel Volume | 0.22 |
Performance History
| Week | +10.73% |
| Month | +14.37% |
| Quarter | +13.47% |
| 6 Months | +74.01% |
| YTD | +86.19% |
| Year | +351.34% |
| 3 Years | +321.25% |
| 10 Years | +175.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $10.11 | 359,498 |
| 2026-06-24 | $10.04 | 1,903,500 |
| 2026-06-23 | $9.91 | 1,631,500 |
| 2026-06-22 | $9.40 | 1,393,700 |
| 2026-06-18 | $8.72 | 7,434,800 |
| 2026-06-17 | $9.13 | 1,963,100 |
| 2026-06-16 | $8.74 | 2,618,700 |
| 2026-06-15 | $8.47 | 970,600 |
| 2026-06-12 | $8.45 | 1,106,300 |
| 2026-06-11 | $8.10 | 1,074,300 |
| 2026-06-10 | $8.18 | 1,109,200 |
| 2026-06-09 | $8.01 | 1,332,700 |
| 2026-06-08 | $7.87 | 1,083,000 |
| 2026-06-05 | $7.93 | 1,267,700 |
| 2026-06-04 | $8.42 | 1,224,000 |
| 2026-06-03 | $8.44 | 1,051,900 |
| 2026-06-02 | $8.36 | 1,380,100 |
| 2026-06-01 | $9.22 | 1,193,100 |
| 2026-05-29 | $9.00 | 963,900 |
| 2026-05-28 | $8.84 | 1,178,100 |
| 2026-05-27 | $8.73 | 1,605,800 |
| 2026-05-26 | $8.84 | 3,651,400 |
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
đ° Latest News
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
Zacks âĸ 2026-06-18T13:55:02Z
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St. âĸ 2026-06-09T11:38:22Z
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
Zacks âĸ 2026-05-27T13:55:02Z
3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%
Simply Wall St. âĸ 2026-05-13T11:35:34Z
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?
Insider Monkey âĸ 2026-05-05T17:05:01Z
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth
Simply Wall St. âĸ 2026-05-05T12:52:58Z
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX)
Simply Wall St. âĸ 2026-02-13T12:10:57Z
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully
Simply Wall St. âĸ 2025-11-24T11:21:03Z
Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders
Simply Wall St. âĸ 2025-10-28T10:01:38Z
Discover Immix Biopharma And 2 Other Promising Penny Stocks
Simply Wall St. âĸ 2025-09-04T18:05:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $29,956,415 | $22,674,680 | $16,141,113 | $8,218,948 |
| Net Non Operating Interest Income Expense | $555,526 | $1,017,354 | $572,006 | $-497 |
| Operating Expense | $29,956,415 | $22,674,680 | $16,141,113 | $8,218,948 |
| General And Administrative Expense | $13,697,817 | $11,381,978 | $7,406,082 | $4,023,170 |
| Interest Expense | - | - | $0 | $497 |
| Interest Expense Non Operating | - | - | $0 | $497 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-29,438,613 | $-21,613,376 | $-15,426,048 | $-8,229,713 |
| Net Interest Income | $555,526 | $1,017,354 | $572,006 | $-497 |
| Interest Income | $555,526 | $1,017,354 | $572,006 | $0 |
| Normalized Income | $-29,438,613 | $-21,613,376 | $-15,426,048 | $-8,229,713 |
| Net Income From Continuing And Discontinued Operation | $-29,438,613 | $-21,613,376 | $-15,426,048 | $-8,229,713 |
| Total Operating Income As Reported | $-29,956,415 | $-22,674,680 | $-16,141,113 | $-8,218,948 |
| Net Income Common Stockholders | $-29,438,613 | $-21,613,376 | $-15,426,048 | $-8,229,713 |
| Net Income | $-29,438,613 | $-21,613,376 | $-15,426,048 | $-8,229,713 |
| Net Income Including Noncontrolling Interests | $-29,438,613 | $-21,698,363 | $-15,595,522 | $-8,229,713 |
| Net Income Continuous Operations | $-29,438,613 | $-21,698,363 | $-15,595,522 | $-8,229,713 |
| Pretax Income | $-29,400,889 | $-21,657,326 | $-15,569,107 | $-8,219,445 |
| Interest Income Non Operating | $555,526 | $1,017,354 | $572,006 | $0 |
| Operating Income | $-29,956,415 | $-22,674,680 | $-16,141,113 | $-8,218,948 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.89 | $-0.76 | $-0.89 | $-0.59 |
| Basic EPS | $-0.89 | $-0.76 | $-0.89 | $-0.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-29,591,914 | $-22,559,292 | $-16,135,645 | $-8,216,813 |
| Reconciled Depreciation | $364,501 | $115,388 | $5,468 | $2,135 |
| EBITDA (Bullshit earnings) | $-29,591,914 | $-22,559,292 | $-16,135,645 | $-8,216,813 |
| EBIT | $-29,956,415 | $-22,674,680 | $-16,141,113 | $-8,218,948 |
| Diluted Average Shares | $32,965,706 | $28,285,637 | $17,341,146 | $13,887,309 |
| Basic Average Shares | $32,965,706 | $28,285,637 | $17,341,146 | $13,887,309 |
| Diluted NI Availto Com Stockholders | $-29,438,613 | $-21,613,376 | $-15,426,048 | $-8,229,713 |
| Minority Interests | $0 | $84,987 | $169,474 | $0 |
| Tax Provision | $37,724 | $41,037 | $26,415 | $10,268 |
| Research And Development | $16,258,598 | $11,292,702 | $8,735,031 | $4,195,778 |
| Selling General And Administration | $13,697,817 | $11,381,978 | $7,406,082 | $4,023,170 |
| Other Gand A | $13,697,817 | $11,381,978 | $7,406,082 | $4,023,170 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $93,796,170 | $13,251,203 | $16,405,114 | $13,159,805 |
| Total Assets | $104,840,341 | $22,947,872 | $19,925,160 | $14,908,101 |
| Total Non Current Assets | $3,602,586 | $2,750,038 | $137,410 | $10,284 |
| Other Non Current Assets | $20,418 | $20,418 | - | $6,724 |
| Non Current Deferred Assets | $93,630 | $0 | $87,229 | $6,724 |
| Current Assets | $101,237,755 | $20,197,834 | $19,787,750 | $14,897,817 |
| Other Current Assets | $150,721 | $32,271 | $44,582 | $78,067 |
| Prepaid Assets | $677,608 | $509,239 | $1,061,194 | $1,127,331 |
| Receivables | $0 | $1,974,370 | $1,172,183 | $255,705 |
| Taxes Receivable | $0 | $1,974,370 | $1,172,183 | $255,705 |
| Cash Cash Equivalents And Short Term Investments | $100,409,426 | $17,681,954 | $17,509,791 | $13,436,714 |
| Cash And Cash Equivalents | $93,928,566 | $17,681,954 | $17,509,791 | $13,436,714 |
| Cash Financial | - | - | $17,509,791 | $13,436,714 |
| Debt | ||||
| Total Debt | $1,072,964 | $1,074,770 | $0 | - |
| Long Term Debt And Capital Lease Obligation | $933,625 | $1,009,551 | $0 | - |
| Current Debt And Capital Lease Obligation | $139,339 | $65,219 | - | - |
| Current Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,044,171 | $9,696,669 | $3,721,783 | $1,748,296 |
| Total Non Current Liabilities Net Minority Interest | $933,625 | $1,009,551 | $0 | $475,000 |
| Current Liabilities | $10,110,546 | $8,687,118 | $3,721,783 | $1,273,296 |
| Payables And Accrued Expenses | $9,029,044 | $7,963,738 | $3,143,929 | $1,273,296 |
| Payables | $5,442,737 | $5,388,494 | $1,433,022 | $143,074 |
| Accounts Payable | $5,442,737 | $5,388,494 | $1,433,022 | $143,074 |
| Current Notes Payable | - | - | - | $0 |
| Interest Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $93,796,170 | $13,251,203 | $16,405,114 | $13,159,805 |
| Total Equity Gross Minority Interest | $93,796,170 | $13,251,203 | $16,203,377 | $13,159,805 |
| Stockholders Equity | $93,796,170 | $13,251,203 | $16,405,114 | $13,159,805 |
| Gains Losses Not Affecting Retained Earnings | $60,160 | $-1,056 | $134,666 | $87,021 |
| Other Equity Adjustments | $60,160 | $-1,056 | $134,666 | $87,021 |
| Retained Earnings | $-104,463,284 | $-75,024,671 | $-53,411,295 | $-37,985,247 |
| Other | ||||
| Treasury Shares Number | $72,363 | $72,363 | $72,363 | $72,363 |
| Ordinary Shares Number | $52,951,103 | $27,540,020 | $19,922,356 | $13,892,122 |
| Share Issued | $53,023,466 | $27,612,383 | $19,994,719 | $13,964,485 |
| Tangible Book Value | $93,796,170 | $13,251,203 | $16,405,114 | $13,159,805 |
| Invested Capital | $93,796,170 | $13,251,203 | $16,405,114 | $13,159,805 |
| Working Capital | $91,127,209 | $11,510,716 | $16,065,967 | $13,624,521 |
| Capital Lease Obligations | $1,072,964 | $1,074,770 | $0 | - |
| Total Capitalization | $93,796,170 | $13,251,203 | $16,405,114 | $13,159,805 |
| Minority Interest | $0 | $0 | $-201,737 | $0 |
| Treasury Stock | $99,963 | $99,963 | $99,963 | $99,963 |
| Additional Paid In Capital | $198,293,956 | $88,374,131 | $69,779,706 | $51,156,597 |
| Capital Stock | $5,301 | $2,762 | $2,000 | $1,397 |
| Common Stock | $5,301 | $2,762 | $2,000 | $1,397 |
| Long Term Capital Lease Obligation | $933,625 | $1,009,551 | $0 | - |
| Current Capital Lease Obligation | $139,339 | $65,219 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $942,163 | $658,161 | $577,854 | - |
| Current Accrued Expenses | $3,586,307 | $2,575,244 | $1,710,907 | $1,130,222 |
| Net PPE | $3,488,538 | $2,729,620 | $50,181 | $3,560 |
| Accumulated Depreciation | $-293,001 | $-47,255 | $-14,314 | - |
| Gross PPE | $3,781,539 | $2,776,875 | $64,495 | $3,560 |
| Leases | $1,244,741 | $0 | - | - |
| Construction In Progress | $0 | $938,768 | $0 | - |
| Other Properties | $1,565,985 | $844,740 | $60,599 | $3,560 |
| Machinery Furniture Equipment | $3,896 | $3,896 | $3,896 | - |
| Buildings And Improvements | $966,917 | $989,471 | $0 | - |
| Properties | $0 | $0 | $0 | - |
| Other Short Term Investments | $6,480,860 | $0 | - | - |
| Preferred Stock | - | $0 | $0 | $0 |
| Long Term Provisions | - | - | - | $475,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,663,229 | $-15,772,782 | $-11,423,527 | $-7,408,303 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,930,304 | $-14,595,102 | $-11,371,438 | $-7,408,303 |
| Cash Flow From Continuing Operating Activities | $-23,930,304 | $-14,595,102 | $-11,371,438 | $-7,408,303 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-732,925 | $-1,177,680 | $-52,089 | - |
| Investing Cash Flow | $-7,213,785 | $-1,177,680 | $-52,089 | $0 |
| Cash Flow From Continuing Investing Activities | $-7,213,785 | $-1,177,680 | $-52,089 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $107,392,716 | $15,946,078 | $15,695,510 | $3,388,750 |
| Financing Cash Flow | $107,386,859 | $15,948,567 | $15,463,512 | $3,232,063 |
| Cash Flow From Continuing Financing Activities | $107,386,859 | $15,948,567 | $15,463,512 | $3,232,063 |
| Net Other Financing Charges | $-136,999 | - | $-234,616 | $-6,724 |
| Net Common Stock Issuance | $107,392,716 | $15,946,078 | $15,695,510 | $3,288,787 |
| Common Stock Issuance | $107,392,716 | $15,946,078 | $15,695,510 | $3,388,750 |
| Repurchase Of Capital Stock | - | - | $0 | $-99,963 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $9,596 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $93,928,566 | $17,681,954 | $17,509,791 | $13,436,714 |
| Beginning Cash Position | $17,681,954 | $17,509,791 | $13,436,714 | $17,644,478 |
| Effect Of Exchange Rate Changes | $3,842 | $-3,622 | $33,092 | $-31,524 |
| Changes In Cash | $76,242,770 | $175,785 | $4,039,985 | $-4,176,240 |
| Proceeds From Stock Option Exercised | $131,142 | $2,489 | $2,618 | $0 |
| Net Investment Purchase And Sale | $-6,480,860 | $0 | - | - |
| Purchase Of Investment | $-6,480,860 | $0 | - | - |
| Net PPE Purchase And Sale | $-732,925 | $-1,177,680 | $-52,089 | $0 |
| Purchase Of PPE | $-732,925 | $-1,177,680 | $-52,089 | $0 |
| Change In Working Capital | $2,701,933 | $3,967,300 | $1,652,908 | $195,206 |
| Change In Other Current Liabilities | $-98,006 | $2,852 | $0 | - |
| Change In Other Current Assets | $0 | $-20,418 | $0 | - |
| Change In Payables And Accrued Expense | $1,027,161 | $4,401,623 | $2,434,467 | $1,122,637 |
| Change In Payable | $1,027,161 | $4,401,623 | $2,434,467 | $1,131,736 |
| Change In Account Payable | $1,027,161 | $4,401,623 | $2,434,467 | $1,131,736 |
| Change In Prepaid Assets | $-286,729 | $554,770 | $111,842 | $-691,047 |
| Change In Receivables | $2,059,507 | $-971,527 | $-893,401 | $-236,384 |
| Stock Based Compensation | $2,441,875 | $3,020,573 | $2,565,708 | $624,069 |
| Depreciation Amortization Depletion | $364,501 | $115,388 | $5,468 | $2,135 |
| Depreciation And Amortization | $364,501 | $115,388 | $5,468 | $2,135 |
| Depreciation | $364,501 | $115,388 | $5,468 | $2,135 |
| Net Income From Continuing Operations | $-29,438,613 | $-21,698,363 | $-15,595,522 | $-8,229,713 |
| Repayment Of Debt | - | - | $0 | $-50,000 |
| Common Stock Payments | - | - | $0 | $-99,963 |
| Net Issuance Payments Of Debt | - | - | $0 | $-50,000 |
| Net Short Term Debt Issuance | - | - | $0 | $-50,000 |
| Short Term Debt Payments | - | - | $0 | $-50,000 |
| Change In Accrued Expense | - | - | $0 | $-9,099 |
| Change In Interest Payable | - | - | $0 | $-9,099 |
| Issuance Of Debt | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Other Non Cash Items | - | - | - | $100,000 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-20